Say goodbye to the US$101m licence fee with EDW Pharma (formerly ITF Pharma).
IMO the chances of another company/partner licencing VivaGel to do an another Phase 3 trial themselves in the US is ZERO.
So the USA (the largest single pharmaceutical market in the world) and FDA remain the boogeymen for Starpharma. None of Starpharma’s 3 commercialised products have got FDA approval. This says a lot and goes to the lack of credibility this company has.
At least CM finally acknowledged in writing that Starpharma did in fact receive a Complete Response Letter from the FDA way back in 2018. Something that astonishingly, previous management could not bring themselves to do.
This year has certainly started off terribly for the new CEO and shareholders and I fear there’s more pain to come in 2024 without AstraZeneca coming to the party.
- Forums
- ASX - By Stock
- SPL
- Ann: VivaGel BV US FDA Appeal Outcome
Ann: VivaGel BV US FDA Appeal Outcome, page-9
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.11M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 14171 | 9.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.1¢ | 1908 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14171 | 0.090 |
1 | 127200 | 0.087 |
1 | 6395 | 0.086 |
3 | 86000 | 0.085 |
1 | 32500 | 0.084 |
Price($) | Vol. | No. |
---|---|---|
0.091 | 1908 | 1 |
0.092 | 5652 | 1 |
0.093 | 65000 | 1 |
0.095 | 40000 | 1 |
0.097 | 50000 | 1 |
Last trade - 08.50am 15/08/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online